Key Takeaways for Boston Scientific Stock as of July 2026
- Beat Across the Board: Q2 adjusted EPS of $0.86 topped Street’s $0.83 estimate.
- Guidance Cut: Boston Scientific trimmed full-year 2026 organic revenue growth to 5% to 6% and adjusted EPS to $3.28 to $3.32, citing sudden WATCHMAN and EP slowdowns.
- WATCHMAN Reversal: Full-year WATCHMAN growth guidance fell to flat to low-single digits after US standalone procedures declined in the low teens YoY in Q2.
- Mahoney’s Admission: CEO Michael Mahoney told investors, “This update today is not the outcome we planned,” taking responsibility for the guide-down even as 75% of the business keeps growing near 6%.
Boston Scientific Beats Q2 Estimates, Then Guts Its Own Guide
Boston Scientific (BSX) posted second-quarter 2026 revenue of $5.442 billion on July 29, growing 7.53% year over year and beating the Street’s $5.366 billion estimate by 1.42%. Adjusted earnings per share of $0.86 climbed 15% from a year earlier and cleared the high end of management’s own $0.82 to $0.84 guidance range. Boston Scientific stock still slipped after the print, because the same call that delivered the beat also delivered a guidance cut for the rest of the year.
The tax line did a lot of the lifting. CFO Jon Monson said the adjusted tax rate fell to 10.4% in the quarter, better than expected and loaded with favorable discrete items, and that swing is what pushed EPS past guidance rather than any surprise in operations. Adjusted operating margin came in at 28.4%, up 70 basis points year over year, while adjusted gross margin reached 70.3%, an 80 basis point improvement.
Management now expects full-year 2026 organic revenue growth of 5% to 6%, down from its prior framework, with adjusted EPS guided to $3.28 to $3.32. Third-quarter organic growth is guided to just 3% to 5%. Two businesses are doing the damage. WATCHMAN, the left atrial appendage closure device, saw its second-half global outlook cut to a mid-to-high-single-digit decline after new clinical evidence altered physician referral patterns and slowed US standalone procedure growth by low teens. Electrophysiology fared little better: Boston Scientific now expects flat global EP growth in the back half of the year after competitors ate into its roughly 80% share of the US PFA (pulse field ablation) market faster than the company had modeled.
CEO Michael Mahoney did not dress up the miss on Q2 2026 earnings call: “This update today is not the outcome we planned or what you have come to expect from us.” He also took personal ownership of the reduction, tying it directly to WATCHMAN and EP rather than the broader portfolio. That distinction matters, because the other 75% of Boston Scientific’s revenue, spanning Interventional Cardiology, Neuromodulation, and Interventional Oncology, is still growing near 6% and is expected to hold that pace through the second half.
To bridge the gap, Boston Scientific unveiled a restructuring program targeting $500 million in run-rate savings by the end of 2029, with more than half realized by the end of 2027. Mahoney flagged 2028 as the turning point, pointing to seven new product launches, including FARAWAVE Ultra in electrophysiology and the pending Penumbra acquisition, that carry a combined addressable market above $25 billion. Until then, the company’s own weighted average market growth rate estimate has dropped roughly a point to 7% to 8%, and management is not underwriting any WATCHMAN or EP recovery in 2027.
TIKR Prices Boston Scientific Stock at $68, Betting on a 2030 Turnaround
TIKR’s mid-case model values Boston Scientific at $68 by December 2030, implying 47% total return from the current price of $46, or 9% annualized over 4.4 years.
That return outpaces what investors typically expect from a slow-and-steady medical device compounder, positioning Boston Scientific stock as a name priced for patience rather than a near-term re-rating.
The model’s runway makes sense against a company still growing three-quarters of its revenue near 6% while WATCHMAN and EP absorb a temporary setback rather than a permanent one. Boston Scientific’s $500 million restructuring program and its 2028 launch slate, from FARAWAVE Ultra to the Penumbra deal, give the target time to reach without leaning on WATCHMAN or EP snapping back sooner.
Should You Invest in Boston Scientific Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Boston Scientific Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Boston Scientific Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze BSX stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
